Forte Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBRX research report →
Range $77 – $77
Price Chart
About the company
Forte Biosciences, Inc. is a U. S.
- CEO
- Paul A. Wagner
- IPO
- 2017
- Employees
- 23
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on FBRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.63B
- P/E
- -16.77
- PEG
- -0.43
- P/S
- 0.00
- P/B
- 9.96
- EV/EBITDA
- -18.37
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -94.82%
- ROIC
- -48.53%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-64,000-64.1%
- Op Income
- $-70,657,000
- Net Income
- $-69,375,000-95.5%
- EPS
- $-4.71+61.3%
- OCF Growth
- -65.5%
- FCF Growth
- -65.7%
- 52W High
- $77.20
- 52W Low
- $10.11
- 50D MA
- $54.00
- 200D MA
- $32.96
- Beta
- 2.65
- RSI (14)
- 84
- Avg Volume
- 1.36M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Forte Biosciences said its FB-401 atopic dermatitis program is on track for a third-quarter readout, with a strong cash position and expanded patent coverage supporting the development plan.· May 10, 2021
- Ended the quarter with approximately $54.8 million in cash and cash equivalents, which management said funds at least the next 12 months.
- FB-401 completed enrollment in the randomized controlled phase 2 study, enrolling 154 subjects versus an original target of 124.
- Management said the trial readout is expected in the third quarter and is using EASI-50, EASI-75, EASI-90 and IGA-related endpoints.
- Two additional patents issued during the period, bringing the U.S. patent count to 11, with filings progressing in more than 15 ex-U.S. countries.
- An open-label extension has been initiated for phase 2 subjects, including placebo patients, focused on safety over one year.
Tony Riley said Forte ended Q1 2021 with approximately $54.8 million in cash and cash equivalents and cash utilization of $4.0 million for the quarter. Research and development expense was $1.4 million in the first quarter of 2021 versus $3.3 million in the first quarter of 2020, while general and administrative expense was $0.7 million versus $1.4 million year over year. Loss per share was $0.36 for the quarter ended March 31, 2021, compared with $0.97 a year earlier, and shares outstanding were 13.5 million. Management said the cash balance should fund operations for at least the next 12 months, and they expect R&D expense to increase over the next 12 months as FB-401 development continues.
Paul Wagner emphasized the large unmet need in atopic dermatitis, especially for pediatric patients, and positioned FB-401 as a potentially important non-chemical, live biotherapeutic option. He said the company is focused on advancing the phase 2 program, expects the data in the third quarter, and is thinking about an integrated global development plan that could include Europe and Asia. His tone was constructive and optimistic, especially around the strong enrollment, FDA Fast Track designation, and the company’s expanding IP portfolio.
Tony Riley focused on the company’s cash runway and expense profile. He highlighted approximately $54.8 million in cash and cash equivalents, $4.0 million in Q1 cash utilization, and said that should be sufficient to fund operations for at least the next 12 months. He also noted R&D expense of $1.4 million versus $3.3 million year over year and G&A expense of $0.7 million versus $1.4 million, with the year-over-year changes tied to clinical development, manufacturing, professional fees, headcount growth, and non-cash stock compensation.
Analysts pressed on endpoint selection, asking why EASI-50 was used in phase 2 instead of IGA; management said IGA is typically a phase 3 endpoint, while EASI-50 is common for smaller phase 2 trials, and they are also looking at EASI-75 and EASI-90. Questions also focused on FDA oversight, open-label extension plans, age-group differences, device/human factors work, Europe/Asia development, and what efficacy delta would be clinically meaningful. Management said the open-label extension has started and will include placebo patients, the spray device is already used in an approved product and is not expected to be problematic, and a 10 to 15 point EASI difference versus placebo could be clinically meaningful if safety is clean.
The call reinforced that FB-401 has a clear near-term catalyst with phase 2 data expected in the third quarter, and enrollment came in above target at 154 subjects. Management also pointed to a strong cash runway, FDA Fast Track designation, and expanding intellectual property as support for the program. They were upbeat about parent interest, compliance with the spray regimen, and the possibility of a broad pediatric-to-adult label.
The biggest risk is that the company still has no readout from the randomized phase 2 study, so the third-quarter data will be critical. Management acknowledged that FDA will ultimately define the safety database and pivotal requirements, and it is still working through Europe-specific regulatory issues. The program also faces the usual clinical risk that efficacy may not be strong enough, even though management said a relatively modest EASI difference could still work if safety is clean.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.1%
- Shares Outstanding
- 21.23M
- Float Shares
- 17.85M
of shares held by institutions
71 13F filers
Buy/sell ratio 0.03. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Orbimed Advisors LLC | 1.58M | ▲ 380.75K |
| Fred Alger Management, LLC | 1.44M | ▲ 165.73K |
| Jupiter Topco LLC | 1.37M | ▲ 1.37M |
| Janus Henderson Group Ltd. | 1.19M | ▼ 237.72K |
| Mpm Bioimpact LLC | 987.45K | ▼ 13.23K |
| Tcg Crossover Management, LLC | 920.00K | ▲ 920.00K |
| Tybourne Capital Management (Hk) Ltd | 786.65K | 0 |
| Woodline Partners LP | 712.75K | ▲ 380.77K |
| Adage Capital Partners Gp, L.L.C. | 700.00K | ▼ 250.00K |
| Integral Health Asset Management, LLC | 675.00K | ▲ 525.00K |
| Millennium Management LLC | 655.20K | ▲ 317.22K |
| Vanguard Group Inc | 582.26K | ▲ 15.52K |
Held by 1 ETFs
Biggest fund positions in FBRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 27, 26 | Kornfeld Steven | other | 3,960 |
| Aug 27, 26 | Kornfeld Steven | sell | 1,200 |
| Aug 27, 26 | Kornfeld Steven | sell | 800 |
| Aug 27, 26 | Kornfeld Steven | sell | 1,000 |
| Aug 27, 26 | Kornfeld Steven | sell | 1,000 |
| Aug 27, 26 | Kornfeld Steven | sell | 2,000 |
| Aug 27, 26 | Kornfeld Steven | sell | 31,000 |
| Aug 27, 26 | Kornfeld Steven | sell | 18,353 |
| Aug 27, 26 | Brun Scott C. | sell | 2,000 |
| Aug 27, 26 | Brun Scott C. | sell | 1,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FBRX coverage
Recent articles, reports, and earnings notes.
No research on FBRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FBRX report →Alger Dynamic Opportunities Fund Q3 2026 Portfolio Update
seekingalpha.com · Oct 29
Squarepoint Ops LLC Reduces Position in Forte Biosciences, Inc. $FBRX
defenseworld.net · Sep 24
argenx Completes Acquisition of Forte Biosciences, Inc.
globenewswire.com · Aug 27
Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?
gurufocus.com · Aug 12
Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?
prnewswire.com · Aug 12
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
gurufocus.com · Aug 11
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
businesswire.com · Aug 11
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
gurufocus.com · Aug 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.